We are a therapeutics company leveraging human milk biology to create new medicines to transform gut-brain axis (GBA) disorders with large populations underserved by current treatment options. Our initial drug candidates are based on bioactive oligosaccharides naturally produced in human milk, or HMOs, which directly modulate the immune system and other human cells, as well as the gut microbiome.

We believe our synthetic biology-manufactured human milk oligosaccharide, or HMO, drug candidates have the potential to affect multiple pathways implicated in GBA disorders and certain inflammatory disorders, while reproducing the favorable safety and tolerability profile observed of HMOs. We are prioritizing the development of our drug candidates for disorders where available treatment options are inadequately serving people living with GBA disorders due to safety or tolerability issues and where we have the potential to redefine the standard of care.